Twitter Updates

    follow me on Twitter

    My Profile

    • EXPERTISE -
      Authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; issues and crisis management. Frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!

    About This Blog

    • Eye on FDA is published by Mark Senak of Fleishman-Hillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of Fleishman-Hillard or its clients.

    My Favorite Dogs

    • January20063_005
      Nick and Nora

    Stats

    • eXTReMe Tracker

    Eye on FDA edrugsearch blog ranking

    • Healthcare 100

    Syndication

    « Weekly Roundup 01/16/09 | Main | Ups and Downs of Health IT »

    January 18, 2009

    TrackBack

    TrackBack URL for this entry:
    http://www.typepad.com/services/trackback/6a00d83451bf5969e2010536d647e7970b

    Listed below are links to weblogs that reference Interesting Article on Pharma and Social Media :

    Comments

    Daniel Ghinn

    The Internet allows pharmaceuticals to get closer to patients than they ever did offline. Naturally that forces them to ask new questions about what they are allowed to say and how to handle what consumers say.

    Of course there are fears over adverse events reporting or negative conversations about their brands, but the bottom line is, if drug companies themselves don't interact with patients online, somebody else will. In fact, somebody else probably already is - if not a competitor then any number of personal blogs or patient forums.

    It will be far better for drug companies who host the conversation than those who merely observe it from afar - or worse still, those who miss it alltogether.

    More at http://www.digitalstrategyconsultancy.com/?p=3

    Verify your Comment

    Previewing your Comment

    This is only a preview. Your comment has not yet been posted.

    Working...
    Your comment could not be posted. Error type:
    Your comment has been posted. Post another comment

    The letters and numbers you entered did not match the image. Please try again.

    As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

    Having trouble reading this image? View an alternate.

    Working...

    Post a comment

    Subscribe / Email Me

    Enter your email address:

    Delivered by FeedBurner

    Search

    • Google

      WWW
      eyeonfda.com

    September 2010

    Sun Mon Tue Wed Thu Fri Sat
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30